MIAMI, FL -- (MARKET WIRE) -- November 28, 2006 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced today that the European Medicines Agency (“EMEA”) has determined that the Marketing Authorization Application (“MAA”) for orBec® for the treatment of gastrointestinal Graft-versus-Host disease (“GI GVHD”) is valid. Validation of the MAA indicates that DOR’s application is complete and that the review process has begun.
